^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    melphalan

    i
    Other names: L-PAM, L-sarcolysin, phenylalanine mustard
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    7d
    Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (clinicaltrials.gov)
    P=N/A, N=57, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=30 --> 57
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • mesna • busulfan
    15d
    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders (clinicaltrials.gov)
    P1/2, N=29, Recruiting, Washington University School of Medicine | Trial completion date: Apr 2031 --> Apr 2033 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea
    16d
    HOVON 95 MM: Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=1503, Completed, Stichting Hemato-Oncologie voor Volwassenen Nederland | Active, not recruiting --> Completed
    Trial completion
    |
    CD34 (CD34 molecule)
    |
    lenalidomide • bortezomib • prednisone • dexamethasone • melphalan
    28d
    Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma. (PubMed, Transfus Apher Sci)
    An algorithm-driven, G-CSF-only mobilization with pre-emptive Plerixafor use based on CD34 counts resulted in 100 % successful collections, early engraftment, minimal plerixafor use, and no mobilization failures. This approach avoids chemotherapy toxicity, optimizes Plerixafor use, and prevents transplant delays.
    Journal
    |
    CD34 (CD34 molecule)
    |
    melphalan • plerixafor
    1m
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=60, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
    1m
    Off-the-shelf NK Cells + SCT for Myeloid Malignancies (clinicaltrials.gov)
    P2, N=24, Completed, M.D. Anderson Cancer Center | Phase classification: P1/2 --> P2
    Phase classification
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • DEK (DEK Proto-Oncogene)
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • Chr del(5q)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    1m
    Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    cyclophosphamide • melphalan • fludarabine IV • Inrebic (fedratinib)
    1m
    CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, Hackensack Meridian Health | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • carfilzomib • melphalan • Neupogen (filgrastim) • dexamethasone injection
    1m
    Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (clinicaltrials.gov)
    P1/2, N=15, Not yet recruiting, University of Wisconsin, Madison
    New P1/2 trial
    |
    melphalan • Opdualag (nivolumab/relatlimab-rmbw) • Melblez Kit (melphalan hepatic delivery system) • relatlimab (BMS-986016)
    1m
    Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=244, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Venclexta (venetoclax) • melphalan • fludarabine IV • busulfan
    1m
    Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Oct 2025 --> Feb 2026
    Trial initiation date
    |
    Venclexta (venetoclax) • decitabine • melphalan
    1m
    Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    melphalan • Blenrep (belantamab mafodotin-blmf)